Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Sell
25
ACON Quote, Financials, Valuation and Earnings
Last price:
$7.37
Seasonality move
:
-17.78%
Day range:
$6.78 - $7.15
52-week range:
$6.20 - $3,499.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.16x
P/B ratio:
4.29x
Volume:
12.3K
Avg. volume:
73.3K
1-year change:
-99.73%
Market cap:
$4.2M
Revenue:
$45.7K
EPS (TTM):
-$9.09
Analysts' Opinion
-
Consensus RatingAclarion has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Aclarion has an estimated upside of 164353.31% from its current price of $7.15.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.15.
Fair Value
-
According to the consensus of 1 analyst, Aclarion has 164353.31% upside to fair value with a price target of -- per share.
ACON vs. S&P 500
-
Over the past 5 trading days, Aclarion has overperformed the S&P 500 by 2.95% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aclarion does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aclarion revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Aclarion reported revenues of $14.4K.
Earnings Growth
-
Aclarion has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aclarion reported earnings per share of -$0.15.
Enterprise value:
3.7M
EV / Invested capital:
--
Price / LTM sales:
0.16x
EV / EBIT:
--
EV / Revenue:
81.15x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$34.2K
Return On Assets:
-223.77%
Net Income Margin (TTM):
-12718.26%
Return On Equity:
-614.41%
Return On Invested Capital:
-373.05%
Operating Margin:
-8995.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $60.4K | $75.4K | $45.7K | $13.8K | $10.2K | |
| Gross Profit | -$4.9K | -$300 | -$38.9K | -$5.6K | -$10.3K | |
| Operating Income | -$5.6M | -$4.9M | -$5.5M | -$1.1M | -$1.8M | |
| EBITDA | -$5.4M | -$4.1M | -$6.3M | -$830.1K | -$1.9M | |
| Diluted EPS | -$140,906.54 | -$79,795.25 | -$7,246.64 | -$13,904.91 | -$1,488.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $97.1K | $732.2K | $1.7M | $1.3M | $824.3K | |
| Total Assets | $1.3M | $1.9M | $2.9M | $2.5M | $2.1M | |
| Current Liabilities | $8.4M | $7.6M | $688.7K | $3.2M | $1.2M | |
| Total Liabilities | $8.4M | $7.6M | $688.7K | $3.2M | $1.2M | |
| Total Equity | -$7.1M | -$5.7M | $2.2M | -$728K | $970.1K | |
| Total Debt | $2.4M | $2M | -- | $1.1M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.9M | -$3.6M | -$5.3M | -$733.8K | -$922.9K | |
| Cash From Investing | -$207.9K | -$119.5K | -$321.9K | -$33.9K | -$60.7K | |
| Cash From Financing | $6.2M | $3.3M | $5M | $1.6M | $125.1K | |
| Free Cash Flow | -$5.2M | -$3.8M | -$5.6M | -$767.7K | -$983.6K | |
ACON
Sector
Market Cap
$4.2M
$35.1M
Price % of 52-Week High
0.2%
44.56%
Dividend Yield
0%
0%
Shareholder Yield
-348.16%
-0.74%
1-Year Price Total Return
-99.73%
-40.62%
Beta (5-Year)
--
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.01
200-day SMA
Sell
Level
$1,134.24
Bollinger Bands (100)
Sell
Level
-155.65 - 910.87
Chaikin Money Flow
Sell
Level
-2.9M
20-day SMA
Sell
Level
$7.96
Relative Strength Index (RSI14)
Sell
Level
33.84
ADX Line
Sell
Level
4.58
Williams %R
Neutral
Level
-77.9884
50-day SMA
Sell
Level
$32.38
MACD (12, 26)
Sell
Level
-10.87
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
1.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-43.0481)
Sell
CA Score
(Annual)
Level (-15.2141)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (21.6215)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
Stock Forecast FAQ
In the current month, ACON has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ACON average analyst price target in the past 3 months is --.
-
Where Will Aclarion Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aclarion share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Aclarion?
Analysts are divided on their view about Aclarion share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aclarion is a Sell and believe this share price will drop from its current level to --.
-
What Is Aclarion's Price Target?
The price target for Aclarion over the next 1-year time period is forecast to be -- according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ACON A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aclarion is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ACON?
You can purchase shares of Aclarion via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aclarion shares.
-
What Is The Aclarion Share Price Today?
Aclarion was last trading at $7.37 per share. This represents the most recent stock quote for Aclarion. Yesterday, Aclarion closed at $7.15 per share.
-
How To Buy Aclarion Stock Online?
In order to purchase Aclarion stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire The Best Stock to Buy in a Bad Market?
Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 73.72% over the past day.
Buy
63
SKX alert for May 6
Skechers USA [SKX] is down 0.07% over the past day.
Sell
20
PTCT alert for May 6
PTC Therapeutics [PTCT] is down 11% over the past day.
